Logo Logo
Hilfe
Hilfe
Switch Language to English

Olarescu, Nicoleta Cristina; Perez-Rivas, Luis G.; Gatto, Federico; Cuny, Thomas; Tichomirowa, Maria A.; Tamagno, Gianluca und Gahete, Manuel D. (2019): Aggressive and Malignant Prolactinomas. In: Neuroendocrinology, Bd. 109, Nr. 1: S. 57-69

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type, accounting for 47-66% of functional pituitary tumors. Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and tumor volume. However, a proportion of prolactinomas exhibit aggressive features (including invasiveness, relevant growth despite adequate dopamine agonist treatment, and recurrence potential) and few may exhibit metastasizing potential (carcinomas). In this context, the clinical, pathological, and molecular definitions of malignant and aggressive prolactinomas remain to be clearly defined, as primary prolactin-secreting carcinomas are similar to aggressive adenomas until the presence of metastases is detected. Indeed, standard molecular and histological analyses do not reflect differences between carcinomas and adenomas at a first glance and have limitations in prediction of the aggressive progression of prolactinomas, wherein the causes underlying the aggressive behavior remain unknown. Herein we present a comprehensive, multidisciplinary review of the most relevant epidemiological, clinical, pathological, genetic, biochemical, and molecular aspects of aggressive and malignant prolactinomas.

Dokument bearbeiten Dokument bearbeiten